JP2020514360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514360A5 JP2020514360A5 JP2019550652A JP2019550652A JP2020514360A5 JP 2020514360 A5 JP2020514360 A5 JP 2020514360A5 JP 2019550652 A JP2019550652 A JP 2019550652A JP 2019550652 A JP2019550652 A JP 2019550652A JP 2020514360 A5 JP2020514360 A5 JP 2020514360A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- peaks
- disease
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 75
- 238000000634 powder X-ray diffraction Methods 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 206010016654 Fibrosis Diseases 0.000 claims 12
- 230000004761 fibrosis Effects 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 230000001363 autoimmune Effects 0.000 claims 6
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 230000000735 allogeneic effect Effects 0.000 claims 5
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000034189 Sclerosis Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 201000004458 Myoma Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 238000002441 X-ray diffraction Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 208000012868 Overgrowth Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 206010003230 arteritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001324 Adrenal atrophy Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004664 Biliary fibrosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000324343 Causa Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000034619 Gingival inflammation Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000219094 Vitaceae Species 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- 239000002095 exotoxin Substances 0.000 claims 1
- 231100000776 exotoxin Toxicity 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000004535 ovarian dysfunction Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022172305A JP2023017840A (ja) | 2017-03-16 | 2022-10-27 | Ｍｋ２阻害剤の形態および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472015P | 2017-03-16 | 2017-03-16 | |
| US62/472,015 | 2017-03-16 | ||
| PCT/US2018/022543 WO2018170199A1 (en) | 2017-03-16 | 2018-03-15 | Forms and compositions of a mk2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172305A Division JP2023017840A (ja) | 2017-03-16 | 2022-10-27 | Ｍｋ２阻害剤の形態および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514360A JP2020514360A (ja) | 2020-05-21 |
| JP2020514360A5 true JP2020514360A5 (enExample) | 2021-04-22 |
Family
ID=63522534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550652A Pending JP2020514360A (ja) | 2017-03-16 | 2018-03-15 | Ｍｋ２阻害剤の形態および組成物 |
| JP2022172305A Pending JP2023017840A (ja) | 2017-03-16 | 2022-10-27 | Ｍｋ２阻害剤の形態および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172305A Pending JP2023017840A (ja) | 2017-03-16 | 2022-10-27 | Ｍｋ２阻害剤の形態および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10882867B2 (enExample) |
| EP (1) | EP3595658A4 (enExample) |
| JP (2) | JP2020514360A (enExample) |
| CN (1) | CN110678178B (enExample) |
| AU (1) | AU2018236286B2 (enExample) |
| CA (1) | CA3054823A1 (enExample) |
| MX (1) | MX393600B (enExample) |
| WO (1) | WO2018170199A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201902326XA (en) | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| CA3054826A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| JP2020514361A (ja) * | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用 |
| JP2020511468A (ja) | 2017-03-16 | 2020-04-16 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤の重水素化アナログおよびその使用 |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| AU2023207395A1 (en) | 2022-01-14 | 2024-07-11 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997038705A1 (en) * | 1996-04-12 | 1997-10-23 | Bristol-Myers Squibb Company | N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors |
| AU2003301226A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corp | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US7790712B2 (en) * | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| CN101360750A (zh) * | 2005-11-23 | 2009-02-04 | 英特芒尼公司 | 应激活化蛋白激酶系统的调节方法 |
| CN101687869A (zh) | 2007-07-16 | 2010-03-31 | 诺瓦提斯公司 | 作为mk2抑制剂的四环内酰胺衍生物 |
| US9126978B2 (en) * | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102464639A (zh) * | 2010-11-16 | 2012-05-23 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
| SG194216A1 (en) * | 2011-04-21 | 2013-11-29 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| KR20150133172A (ko) * | 2013-03-15 | 2015-11-27 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Mk2 억제제 및 이의 용도 |
| WO2014210319A2 (en) * | 2013-06-26 | 2014-12-31 | The Trustees Of Columbia University In The City Of New York | Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds |
| WO2016032882A1 (en) * | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| SG10201902326XA (en) * | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| MX2017008994A (es) | 2015-01-08 | 2018-09-18 | Moerae Matrix Inc | Formulacion de peptidos inhibidores mk2. |
| JP2020511468A (ja) | 2017-03-16 | 2020-04-16 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤の重水素化アナログおよびその使用 |
| JP2020514361A (ja) | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用 |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| CA3054826A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| WO2020236636A1 (en) | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| KR20230044446A (ko) | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
-
2018
- 2018-03-15 CN CN201880032086.2A patent/CN110678178B/zh active Active
- 2018-03-15 US US16/494,725 patent/US10882867B2/en active Active
- 2018-03-15 CA CA3054823A patent/CA3054823A1/en active Pending
- 2018-03-15 WO PCT/US2018/022543 patent/WO2018170199A1/en not_active Ceased
- 2018-03-15 AU AU2018236286A patent/AU2018236286B2/en not_active Ceased
- 2018-03-15 EP EP18768155.6A patent/EP3595658A4/en active Pending
- 2018-03-15 JP JP2019550652A patent/JP2020514360A/ja active Pending
- 2018-03-15 MX MX2019010643A patent/MX393600B/es unknown
-
2020
- 2020-12-29 US US17/136,464 patent/US11629153B2/en active Active
-
2022
- 2022-10-27 JP JP2022172305A patent/JP2023017840A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514360A5 (enExample) | ||
| JP2020511468A5 (enExample) | ||
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| ES2623608T3 (es) | Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida | |
| JP2020523390A5 (enExample) | ||
| JP2020512316A5 (enExample) | ||
| JP6753396B2 (ja) | エンザルタミド結晶形の製造方法 | |
| Wang et al. | Effects of NaOH on formation of ZnO nanorods from ε-Zn (OH) 2 | |
| CN111393446A (zh) | 3,5-二取代的苯炔基化合物晶体 | |
| JP2018538331A5 (enExample) | ||
| EP3846906A1 (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| Su et al. | Effects of Sb-doping on the formation of (K, Na)(Nb, Sb) O3 solid solution under hydrothermal conditions | |
| TWI399375B (zh) | 嗎啉化合物之鹽 | |
| CN103980292B (zh) | 头孢克肟三水合物的结晶方法 | |
| NZ730603A (en) | Mk2 inhibitors and uses thereof | |
| JP4530287B2 (ja) | オキサセフェムの結晶 | |
| JP2010520273A5 (enExample) | ||
| Zhu et al. | Preparation of acicular strontium barium potassium niobate seed crystals | |
| JP7094021B2 (ja) | ３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの多形形態の生成方法 | |
| JP2018080125A (ja) | インドリン化合物のβ型結晶の製造方法 | |
| CN107056860A (zh) | 2－肼基腺苷及其制备方法 | |
| JP6480237B2 (ja) | スコロダイトの製造方法 | |
| JP7094020B2 (ja) | ３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの多形形態の生成方法 | |
| JP5330982B2 (ja) | バテライト型炭酸カルシウムの製造方法 | |
| TWI648267B (zh) | 纈沙坦二鈉鹽新晶型 |